PALB2 Oncogenic Mutations (loss of function alterations)

CI-VAR-00003122Explore in graph →CIViC 3112

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
HER2 Negative Breast Cancer1unmapped disease
PALB2 Oncogenic Mutations (loss of function alterations)	Talazoparib	Predictive	B	Supports Sensitivity Response	3	submitted	EID10856 In a Phase II trial, the efficacy of talazoparib was evaluated in patients with pretreated advanced HER2-negative breast cancer or other solid tumors with mutations in homologous recombination pathway… (full text at CIViC) PMID 36253484 · Gruber et al., 2022 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.